The Business Times
business-time-50

Pfizer

Companies & Markets

Pfizer secures China nod for obesity drug as generics loom

Pfizer has already warned of challenges it expects over the next few years and has said that it does not expect to return to revenue growth until 2029.
Companies & Markets

Pfizer beats Q4 profit estimates on strong drug demand

The drugmaker expects adjusted profit of between US$2.80 and US$3 per share for the coming year, below analysts’ average estimate of US$3.05 per share.
Companies & Markets

Pfizer forecasts 2026 profit below expectations on lower Covid product sales

The US drugmaker is offering about 4.55 million American depositary receipts via an overnight block trade marketed between US$108 to US$111.70 per share.
Companies & Markets

Pfizer looks to sell stake in pandemic vaccine partner BioNTech

Pfizer said it would pay US$86.25 per share in cash, a premium of 3.69 per cent to Metsera’s Friday close.
Companies & Markets

Metsera accepts Pfizer’s US$10 billion bid in ongoing M&A battle

Pfizer is still trying to rebuild in the aftermath of the pandemic, with a cost-cutting programme and planned deals to drive future sales growth.
Companies & Markets

Pfizer boosts profit view as it battles for obesity startup

The tussle for Metsera began with discussions between the company and potential acquirers in early 2024, with both Pfizer and Novo Nordisk, the maker of Wegovy and Ozempic, expressing interest.
Companies & Markets

Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid

The Pfizer-Trump agreement represents a highly personalised, transactional approach to healthcare policy that could set troubling precedents.
Opinion & Features

The Pfizer-Trump deal: A new chapter in drug pricing or political theatre?

Pfizer’s top-selling drugs include the blood-thinner Eliquis, the pneumonia vaccine Prevnar, and a shot and pill for Covid-19.
Consumer & Healthcare

Pfizer’s drug price cuts yield three-year Trump tariff reprieve

In late May, Pfizer agreed to pay a record US$1.25 billion upfront to license an experimental cancer drug from Shenyang-based 3SBio, as well as making a US$100 million equity investment in the Hong Kong-listed biotech company.
Opinion & Features
THE BOTTOM LINE

Why China biotech is getting a DeepSeek moment, too

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More